Use of Continuous-Infusion Ceftolozane/Tazobactam in a Multidrug-Resistant Pseudomonas aeruginosa Urinary Tract Infection in the Outpatient Setting

Annals of Pharmacotherapy

Volumn 51, Issue 8, 2017, Pages 715-716

  Jones, Bruce M ^a   Smith, Bradley ^a   Bland, Christopher M ^a,b  

^a St Joseph's/Candler Health System   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFALEXIN; CEFTOLOZANE PLUS TAZOBACTAM; COTRIMOXAZOLE; LORATADINE;

AGED; ANTIBIOTIC THERAPY; CASE REPORT; COLONY FORMING UNIT; COMBINATION DRUG THERAPY; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; HUMAN; INFUSION PUMP; LETTER; MEDICAL HISTORY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; OUTPATIENT; PRIORITY JOURNAL; PRURITUS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RECURRENT INFECTION; URETER STONE; URINALYSIS; URINARY TRACT INFECTION; URINE CULTURE;

EID: 85024093319     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028017701938     Document Type: Letter

References (4)

1. Liscio JL, Mahoney MV, Hirsch EB., Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections. Int J Antimicrob Agents. 2015;46:266-271.
2. Buck C, Bertram N, Ackermann T. Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion. Int J Antimicrob Agents. 2005;25:62.
3. Nateson S, Pai MP, Lodise TP., Determination of alternative ceftolozane/tazobactam (C/T) dosing regimens for patients with infections due to Pseudomonas aeruginosa with high (C/T) MIC values. Poster presented at: Antimicrobial Pharmacokinetics and Pharmacodynamics, IDWeek 2016; October 26-30; New Orleans, LA.
4. FDA decision summary for ceftolozane/tazobactam. http://www.accessdata.fda.gov/cdrh_docs/reviews/K150556.pdf. Accessed October 18, 2016.